10-Q: Precigen Narrows Loss, Faces Going Concern Doubt

Precigen reported a reduced net loss for the first half of 2025, driven by strategic pipeline prioritization and cost reductions, but faces substantial doubt about its ability to continue as a going concern without additional funding.

Summary

• Net loss for the six months ended June 30, 2025, decreased to $80.8 million from $82.5 million in the prior year period.
• Total revenues increased by 23.3% to $2.2 million for the six months ended June 30, 2025, primarily due to increased product and service volumes from the Exemplar subsidiary.
• Operating expenses decreased by 35.0% to $56.6 million, largely due to a $8.0 million reduction in research and development expenses following the strategic prioritization and closure of ActoBio operations.
• Selling, general and administrative expenses increased by 39.3% to $28.5 million, driven by commercial readiness efforts for PRGN-2012.
• The company recorded a $3.9 million goodwill impairment related to its Exemplar reporting unit in Q2 2025.
• Cash and cash equivalents, along with short-term investments, totaled $59.8 million as of June 30, 2025, down from $97.9 million at December 31, 2024.
• Net cash used in operating activities was $35.3 million for the six months ended June 30, 2025.
• The FDA granted priority review to the Biologics License Application (BLA) for PRGN-2012, with a Prescription Drug User Fee Act (PDUFA) target action date of August 27, 2025.
• The company's accumulated deficit grew to $2.17 billion as of June 30, 2025.
• Shareholders approved an increase in authorized common stock to 700 million shares and an increase in shares available for incentive plans on June 26, 2025.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative. While there are positives like reduced R&D expenses and PRGN-2012's priority review, the explicit 'going concern' warning, significant cash burn, and increased accumulated deficit are major concerns. The company's future is heavily reliant on a single product's approval and subsequent commercial success, coupled with the need for further capital, which introduces substantial risk.

Positives

• Net loss decreased by $1.7 million for the six months ended June 30, 2025, compared to the same period in 2024.
• Total revenues increased by 23.3% to $2.2 million, indicating growth in product and service sales from the Exemplar subsidiary.
• Research and development expenses decreased by 26.6% ($8.0 million) due to strategic pipeline prioritization and the cessation of ActoBio operations, reflecting improved cost management.
• The FDA granted priority review for PRGN-2012's BLA, with a PDUFA target action date of August 27, 2025, indicating significant regulatory progress for the lead product candidate.
• PRGN-2012 has received Breakthrough Therapy Designation and Orphan Drug designation from the FDA, and Orphan Drug Designation from the European Commission, highlighting its potential medical significance.

Negatives

• The company incurred a net loss of $80.8 million for the six months ended June 30, 2025, and has an accumulated deficit of $2.17 billion, indicating continued unprofitability.
• Cash and cash equivalents, along with short-term investments, significantly decreased from $97.9 million at December 31, 2024, to $59.8 million at June 30, 2025.
• Selling, general and administrative expenses increased by 39.3% ($8.0 million) due to commercial readiness efforts, contributing to the cash burn.
• A goodwill impairment charge of $3.9 million was recorded for the Exemplar reporting unit due to lowered financial expectations and projected delays.
• The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern' as current cash and investments are insufficient to fund planned operations for one year without external funding or PRGN-2012 revenue.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to ongoing operating losses and insufficient cash to fund operations for the next 12 months.
• Dependence on the successful development, regulatory approval, and commercialization of product candidates, particularly PRGN-2012.
• Uncertainty regarding the timing and magnitude of future revenues, especially from PRGN-2012, as FDA approval is not guaranteed.
• Need to raise additional capital through equity offerings, debt, or strategic transactions, which may lead to significant shareholder dilution or relinquishing valuable rights.
• Risks inherent in high-risk, early-stage research and development, including dependence on key individuals, intellectual property protection, competition, and technical challenges.
• Volatility of the company's stock price, which could make future equity financings more difficult.
• Potential adverse outcomes from pending and future litigation, including the Edward D. Wright derivative action and Kent v. Precigen lawsuit.
• Exposure to market risk from changes in interest rates affecting the fair value of investments.

Future Outlook

The company anticipates continued operating losses and negative cash flows from operations in the foreseeable future, exclusive of potential revenue from PRGN-2012. Its transition to profitability depends on the successful development, approval, and commercialization of product candidates and achieving sufficient revenues. Commercial readiness efforts for PRGN-2012 are ongoing for a potential launch in the second half of 2025, contingent on FDA approval by the August 27, 2025 PDUFA date. The company plans to focus on strategic partnerships to advance UltraCAR-T programs and continue PRGN-2009 Phase 2 clinical trials under a CRADA with the NCI.

Management Comments

• "We are a dedicated discovery and clinical-stage biopharmaceutical company advancing the next generation of gene and cell therapies with the overall goal of improving outcomes for patients with significant unmet medical needs."
• "We believe that our array of technology platforms uniquely positions us among other biotechnology companies to advance precision medicine."
• "These strategic changes were designed to enable us to focus on the pre-commercialization efforts for PRGN-2012, including supporting regulatory approval, conducting the confirmatory clinical trial, and manufacturing of commercial product."
• "Additionally, we have continued commercial readiness efforts for a potential launch."
• "Our success is dependent upon our ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of our products, successfully commercialize our products, generate revenue, meet our obligations, and, ultimately, attain profitable operations."
• "Based on current projections, management believes that its existing cash, cash equivalents and short-term investments, combined with anticipated potential revenue from the commercialization of PRGN-2012, which is outside of our direct control, will enable us to continue our operations for at least one year from the date of this filing."

Industry Context

Precigen operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on gene and cell therapies. The strategic shift to prioritize PRGN-2012 and seek partnerships for other platforms like UltraCAR-T reflects a common industry trend for smaller biotechs to narrow focus and conserve capital, especially when a lead candidate approaches regulatory decision. The emphasis on 'off-the-shelf' and rapid manufacturing for UltraCAR-T aims to address key challenges in CAR-T therapy, such as cost and logistical complexity, which are significant competitive differentiators if successful. The company's reliance on a single lead product (PRGN-2012) for near-term commercialization places it in a high-risk, high-reward position typical of clinical-stage biotechs awaiting pivotal regulatory approvals.

Comparison to Industry Standards

• Precigen's accumulated deficit of over $2.17 billion is substantial, reflecting the significant R&D investment typical for a clinical-stage biopharmaceutical company, comparable to peers like Bluebird Bio or CRISPR Therapeutics in their early development phases, which also incurred large losses before potential commercialization.
• The cash burn rate, with $35.3 million used in operating activities in six months, is high relative to current revenues, a common characteristic of pre-commercial biotech companies. This rate is comparable to other gene therapy developers like Sarepta Therapeutics or uniQure N.V. during their clinical development stages, where R&D and SG&A expenses outpace early revenues.
• The strategic prioritization of PRGN-2012 and the pausing of other clinical trials (PRGN-3005, PRGN-3007) align with industry practices where companies streamline pipelines to focus resources on the most promising late-stage assets, similar to how companies like Sangamo Therapeutics or Editas Medicine have adjusted their portfolios.
• The PDUFA target action date for PRGN-2012 on August 27, 2025, is a critical near-term catalyst, a common event for biotech companies that can significantly impact valuation, similar to recent BLA/NDA decisions for companies like Vertex Pharmaceuticals (for cystic fibrosis) or BioMarin Pharmaceutical (for gene therapies).
• The 'going concern' warning is a significant red flag, indicating a higher financial risk compared to more established pharmaceutical companies. This is a common disclosure for early-stage biotechs that are not yet profitable and rely heavily on future financing or product approvals, similar to disclosures seen from companies like Athersys or Sorrento Therapeutics in their challenging periods.

Corporate Governance

Legal Proceedings

• Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al: A derivative shareholder action filed in December 2020, stayed in June 2021, alleging claims related to disclosures about the MBP program from May 10, 2017, to March 1, 2019. Plaintiff seeks damages and forfeiture of benefits.
• Kent v. Precigen, Inc.: An individual shareholder lawsuit filed in September 2021, related to MBP program disclosures, demanding inspection of company books and records. The court denied the demurrer and referred the matter to a hearing on the merits in April 2022.
• Indemnification liability related to the sale of Trans Ova: The company has an indemnification accrual of $3.213 million as of June 30, 2025, for certain expenses incurred by the buyer post-close, including patent infringement lawsuits. Payments of $1.862 million in 2024 and $675,000 in 2023 were made against this liability.

Related Party Transactions

• In August 2024, 23,588,234 shares of the 39,878,939 shares sold in a public offering were purchased by related parties and their affiliates, including the Company's Chairman of the Board of Directors and his affiliates, and one executive officer.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises and the conversion of Series A Preferred Stock and Warrants. The 'going concern' warning poses a direct threat to investment value. However, successful PRGN-2012 approval could lead to substantial upside.
• **Employees**: Experienced a workforce reduction of over 20% in August 2024 as part of strategic prioritization. Future employment stability is tied to the company's financial health and PRGN-2012's success.
• **Customers (Exemplar)**: Continued to generate increased product and service revenues, indicating stable or growing demand for MiniSwine models, though the goodwill impairment suggests some challenges in this segment's outlook.
• **Creditors**: The company's 'going concern' doubt and reliance on future capital raises or product approval could impact its creditworthiness and ability to meet obligations, although the line of credit with American State Bank has no outstanding balance.
• **Regulatory Authorities (FDA)**: The company is actively engaged with the FDA for PRGN-2012 BLA review, with a PDUFA date set, indicating a critical juncture in its regulatory pathway.

Next Steps

• Await FDA decision on PRGN-2012 Biologics License Application (BLA) by the PDUFA target action date of August 27, 2025.
• Continue commercial readiness efforts for a potential launch of PRGN-2012 in the second half of 2025.
• Continue enrolling patients in the confirmatory clinical trial for PRGN-2012.
• Pursue strategic partnership opportunities to advance UltraCAR-T programs.
• Continue PRGN-2009 Phase 2 clinical trials under a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI).
• Assess capital resources and potentially raise additional capital through various financing methods if PRGN-2012 approval is delayed or not granted, or if additional funding is needed.

Key Dates

Recommendation

The company presents a high-risk, high-reward profile. While the significant reduction in operating loss and the FDA's priority review for PRGN-2012 are positive developments, the explicit 'going concern' warning and substantial cash burn are critical concerns. The company's future hinges almost entirely on the successful approval and commercialization of PRGN-2012, which is not guaranteed, and its ability to secure additional financing without excessive dilution. A seasoned investor would likely 'hold' to observe the outcome of the PRGN-2012 PDUFA date and the company's ability to address its liquidity challenges, as the risk of capital loss is high, but the potential upside from a successful drug launch is also considerable.

Keywords

Biopharmaceutical, Gene Therapy, Cell Therapy, Immuno-oncology, Autoimmune Disorders, Infectious Diseases, PRGN-2012, RRP, Recurrent Respiratory Papillomatosis, FDA Approval, PDUFA, AdenoVerse, UltraCAR-T, Exemplar Genetics, Going Concern, SEC Filing, 10-Q, Clinical Trials, Biologics License Application